Gamma radiation improves AD pathogenesis in APP/PS1 mouse model by potentiating insulin sensitivity

Area of Science:

• Neuroscience
• Radiology
• Biomedical Science

Background:

• Alzheimer's disease (AD) presents a significant unmet medical need with devastating cognitive and functional impairments.
• Current AD treatments are limited, increasing the socio-economic burden.
• Emerging research suggests therapeutic potential for controlled radiation exposure.

Purpose of the Study:

• To investigate the therapeutic role of gamma irradiation in Alzheimer's disease pathogenesis.
• To evaluate the effects of gamma irradiation on AD-associated pathology and cognitive deficits in a mouse model.

Main Methods:

• Utilized the APP/PS1 transgenic mouse model of Alzheimer's disease.
• Administered a single dose of 4.0 Gy gamma irradiation.
• Assessed behavioral impairments, antioxidant enzyme levels, astrocyte activation, AD-related protein levels (APP, pTau, BACE), neurofibrillary tangle (NFT) formation, and glucose metabolism.

Main Results:

• Gamma irradiation significantly improved behavioral impairments in APP/PS1 mice.
• Radiation exposure increased antioxidant enzymes and reduced astrocyte activation.
• Observed significant reductions in amyloid precursor protein (APP), phosphorylated tau (pTau), BACE, and NFTs.
• Enhanced glucose metabolic functionality and modulated insulin signaling kinases (GSK, ERK, JNK).
• Increased GSK3β (ser 9) levels led to downregulated ERK and JNK phosphorylation, reducing tau hyperphosphorylation and amyloid deposition.

Conclusions:

• A single 4.0 Gy gamma irradiation dose demonstrated therapeutic benefits in an AD mouse model.
• Gamma irradiation potentiates insulin signaling, reduces key AD pathologies, and improves cognitive function.
• This suggests gamma irradiation as a potential novel therapeutic strategy for Alzheimer's disease.